Attention bias modification add‐on to inpatient treatment for young women with anorexia nervosa—A randomized controlled trial — Hadar Dikstein (2022) | RDL Network
Attention bias modification add‐on to inpatient treatment for young women with anorexia nervosa—A randomized controlled trial
Article 2022 en
Authors
HD
Hadar Dikstein
TM
Tal Gilon Mann
RH
Roni Halevi‐Yosef
Abstract
1 min read
Patients with anorexia nervosa (AN) display elevated anxiety and attention biases (ABs) in threat processing. Attention bias modification treatment (ABMT) is considered promising for anxiety disorders, but its potential for AN is limited. In this study, 154 young women hospitalised because of AN were assigned to ED-related and anxiety-related threat stimuli, or to a non-ABMT intervention control condition in a randomized control trial. Hundred-and-ten patients completed the study. ABMT was an add-on to the regular inpatient treatment. Research participants completed two pretreatment training sessions and eight biweekly sessions of ABMT. AB, ED-related symptoms, depression, anxiety and stress were assessed before and after ABMT in the research groups, and, similarly, 5 weeks apart, in the controls. We found that despite the different patterns of change in AB between the three groups following ABMT, the reduction in AB, or the between-group differences in AB-reduction, were not significant. While the severity of ED-symptoms, depression, anxiety and stress was reduced following ABMT, or control condition, in all groups, there were no between-group differences in these changes. Changes in AB were not correlated with baseline and pre-post-treatment changes in ED-related and comorbid symptomatology. Methodological and inpatient treatment-related considerations may explain our negative ABMT-related results.
Zoe S Markomanolaki, Xanthi Tigani, Thomas Siamatras, Flora Bacopoulou, Athanasios N. Tsartsalis, Artemios Artemiadis, Vasileios Megalooikonomou, Dimitriοs Vlachakis, George Chrousos, Christina Darviri
Discussion(0)
No comments yet. Be the first to comment.